PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics Limited announced that all resolutions at their Annual General Meeting were passed by the required majority, reflecting strong shareholder support. As a clinical-stage biotech company, PYC is pioneering RNA therapies aimed at treating genetic diseases, with multiple clinical trials underway. Investors are keenly watching as the company is expected to release human efficacy data for its novel drugs over the next year.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.